...
search icon
nrxp-img

NRX Pharmaceuticals Inc, Common Stock

NRXP

NAQ

$2.85

-$0.09

(-3.06%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$48.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
279.99K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.1 L
$7.33 H
$2.85

About NRX Pharmaceuticals Inc, Common Stock

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNRXPSectorS&P500
1-Week Return-3.06%-0.03%1.53%
1-Month Return-44.12%4.56%4.75%
3-Month Return145.69%1.29%2.77%
6-Month Return53.23%-3.54%12.18%
1-Year Return-42.07%1.59%22.34%
3-Year Return-90.53%13.55%38.91%
5-Year Return-97.32%40.85%80.7%
10-Year Return-97.03%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-907.41K2.00K4.00K5.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.22,"profit":true},{"date":"2022-12-31","value":0.44,"profit":true},{"date":"2023-12-31","value":0.55,"profit":true}]
Gross Profit-(907.41K)(2.00K)(4.00K)(5.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-90740600,"profit":false},{"date":"2021-12-31","value":-200000,"profit":false},{"date":"2022-12-31","value":-400000,"profit":false},{"date":"2023-12-31","value":-500000,"profit":false}]
Gross Margin-(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses6.43K11.90M94.43M44.40M27.58M[{"date":"2019-12-31","value":0.01,"profit":true},{"date":"2020-12-31","value":12.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":47.02,"profit":true},{"date":"2023-12-31","value":29.21,"profit":true}]
Operating Income(6.26K)(51.39M)(115.80M)(44.40M)(27.59M)[{"date":"2019-12-31","value":-626324,"profit":false},{"date":"2020-12-31","value":-5138700000,"profit":false},{"date":"2021-12-31","value":-11579600000,"profit":false},{"date":"2022-12-31","value":-4439700000,"profit":false},{"date":"2023-12-31","value":-2758700000,"profit":false}]
Total Non-Operating Income/Expense-(39.93M)22.71M4.83M(2.06M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-175.8,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":21.26,"profit":true},{"date":"2023-12-31","value":-9.06,"profit":false}]
Pre-Tax Income492.63K(51.78M)(93.06M)(39.82M)(30.16M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-10510.26,"profit":false},{"date":"2021-12-31","value":-18890.94,"profit":false},{"date":"2022-12-31","value":-8082.28,"profit":false},{"date":"2023-12-31","value":-6122,"profit":false}]
Income Taxes84.21K(39.43M)(21.35M)(4.58M)(9.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-46825.64,"profit":false},{"date":"2021-12-31","value":-25352.11,"profit":false},{"date":"2022-12-31","value":-5440.23,"profit":false},{"date":"2023-12-31","value":-10.69,"profit":false}]
Income After Taxes-(12.35M)(71.72M)(35.23M)(30.15M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1234700000,"profit":false},{"date":"2021-12-31","value":-7171500000,"profit":false},{"date":"2022-12-31","value":-3523500000,"profit":false},{"date":"2023-12-31","value":-3015000000,"profit":false}]
Income From Continuous Operations-(1.09M)(93.06M)(39.75M)(36.06M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-108951000,"profit":false},{"date":"2021-12-31","value":-9306300000,"profit":false},{"date":"2022-12-31","value":-3975400000,"profit":false},{"date":"2023-12-31","value":-3605900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income408.43K(12.35M)(71.72M)(35.23M)(30.15M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-3023.06,"profit":false},{"date":"2021-12-31","value":-17558.83,"profit":false},{"date":"2022-12-31","value":-8627,"profit":false},{"date":"2023-12-31","value":-7381.98,"profit":false}]
EPS (Diluted)0.05(2.27)(7.60)(0.62)(0.85)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-4537.6,"profit":false},{"date":"2021-12-31","value":-15200,"profit":false},{"date":"2022-12-31","value":-1240,"profit":false},{"date":"2023-12-31","value":-1700,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NRXP
Cash Ratio 0.08
Current Ratio 0.20

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NRXP
ROA (LTM) -115.97%
ROE (LTM) -682.61%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NRXP
Debt Ratio Lower is generally better. Negative is bad. 5.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -4.22

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NRXP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.90
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is NRX Pharmaceuticals Inc share price today?

NRX Pharmaceuticals Inc (NRXP) share price today is $2.85

Can Indians buy NRX Pharmaceuticals Inc shares?

Yes, Indians can buy shares of NRX Pharmaceuticals Inc (NRXP) on Vested. To buy NRX Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NRXP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of NRX Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of NRX Pharmaceuticals Inc (NRXP) via the Vested app. You can start investing in NRX Pharmaceuticals Inc (NRXP) with a minimum investment of $1.

How to invest in NRX Pharmaceuticals Inc shares from India?

You can invest in shares of NRX Pharmaceuticals Inc (NRXP) via Vested in three simple steps:

  • Click on Sign Up or Invest in NRXP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in NRX Pharmaceuticals Inc shares
What is NRX Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of NRX Pharmaceuticals Inc (NRXP) is $7.33. The 52-week low price of NRX Pharmaceuticals Inc (NRXP) is $1.1.

What is NRX Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of NRX Pharmaceuticals Inc (NRXP) is 2.90

What is the Market Cap of NRX Pharmaceuticals Inc?

The market capitalization of NRX Pharmaceuticals Inc (NRXP) is $48.21M

What is NRX Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of NRX Pharmaceuticals Inc is NRXP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top